Bruker Corporation (NASDAQ: BRKR) is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Today, worldwide more than 9.700 employees are working on this permanent challenge at over 100 locations.
Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
The M&A and Business Development (Strategy) team of the CALID Group drives mergers & acquisitions, post-merger integration and strategic projects, as well as the strategic planning process for our Group. We partner with our management, business divisions, functional and corporate departments to advice and assist them with a problem solving hands on mentality in these high priority areas and projects.
Software Powered by iCIMS
www.icims.com